SEC Filings

10-K
ARRAY BIOPHARMA INC filed this Form 10-K on 08/11/2017
Entire Document
 
[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.


Term
Section Defined
Term
Section Defined
Approved Clinical Study
4.4(a)(i)
Infringement Actions
11.4(a)
Arbitration Tribunal
Array
Array Indemnitees
17.3(a)
Introduction
16.1
Infringing Product 
JCC Chairperson
11.3(a)(i)
3.3
Array Regulatory Filings
4.6(b)
JDRC Chairperson
3.3
Audited Site
4.6(d)(ii)
Joint Clinical Study Proposal
4.4(a)
Auditor
AZ
7.4
11.3(a)(ii)
Joint Commercial Committee /JCC
3.2(a)
AZ Agreement
BEACON Clinical Study
11.3(a)(ii)
4.1(c)
Joint Development and Regulatory Committee /JDRC
3.1(a)
Blocking Patent
6.5
Joint Development Plan
4.4(a)(i)
CAPA
COLUMBUS Clinical Study
Combination Study(ies)
4.6(d)(ii)
4.1(c)
4.5(b)(i)
Liabilities
Liaison
Local Study(ies)
16.1
3.7
4.5(b)(i)
Commercializing Party
2.3(a)
Marketing Materials
5.1(c)
Commercialization Plan
5.1(b)
Materials
9.1(a)
Committee
3.3
Medical Journal
10.4
Committee Dispute
Competing Product
3.5(a)
8.2
NEMO Clinical Study
[ * ]
4.1(c)
14.2(a)(ii)
Confidential Information
Declined Clinical Study
Development Plan
Dispute
Domain Name
10.1
4.4(c)(i)
4.2(a)
17.3
12.6
Non-Performing Party
Novartis
Ono
Ono Indemnitees
Patient Sample
4.4(c)(i)(D)
4.1(c)
Introduction
16.2
4.10
Drug Product
Drug Substance
9.1(b)
9.1(b)
Performing Party
4.4(c)(i)(D)
Education Materials
Effective Date
5.1(c)
Introduction
PFM Agreement
Product Materials
2.4(a)
14.2(a)(vi)
Enforcing Party
Existing Clinical Studies
Expert Dispute
Expert Resolution Notice
11.3(a)(i)
4.1(c)
17.2(a)
17.2(b)
Quality Agreement
Royalty Payments
Royalty Report
Rules
9.4(b)
6.3
6.3(d)
17.3(a)
Experts
Generic Version
Global Study(ies)
17.2(c)
6.4(c)(i)
4.5(b)(iii)
Scientific Meeting
Scientific Paper
Subcontract
10.5
10.4
18.11
Government Official
15.1(f)
Subject Party
11.4(a)
Grant-Back License
Indemnitee
Indemnitor
2.6
16.3
16.3
Sublicensing Party
Supply Agreement
Third Party Claim
2.3(a)
9.4(b)
16.1
 
 
Third Party Technology
Wind-down Period
2.3(a)
14.2(a)(ii)
 
 
Working Group
3.6


14